Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Press brief by Francois-Xavier Mahon, MD, PhD of University Hospital of Bordeaux, Bordeaux, France, on results of the EURO-SKI trial on cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia (CML) patients with deep molecular response held at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.